Completed PHASE3 NCT00095082

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1

Interventions insulin aspart insulin detemir insulin glargine

Updated 7 times since 2017 Last updated: Jan 26, 2017 Started: Sep 30, 2004 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 1 and is currently completed. Novo Nordisk A/S leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abergavenny, United Kingdom , Almere Stad, Netherlands , Alsdorf, Germany , Anaheim, United States , Angers, France , Antibes, France , Apeldoorn, Netherlands , Asheville, United States , Atlanta, United States , Ayr, United Kingdom and 67 more locations